Can tocotrienol reduce time to the first serious adverse event during treatment with FOLFOXIRI for colorectal cancer?

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Journal	Annals of Oncology
Volume	30
Issue number	Suppl. 5
Pages (from-to)	v871
Number of pages	1
ISSN	0923-7534
DOIs	https://doi.org/10.1093/annonc/mdz394.026
Publication status	Published - 2019
Event	ESMO Congress 2019 : Translating science into better cancer patient care - Barcelona, Spain Duration: 27. Sep 2019 → 1. Oct 2019 https://www.esmo.org/Conferences/Past-Conferences/ESMO-Congress-2019

Conference	ESMO Congress 2019
Country	Spain
City	Barcelona
Period	27/09/2019 → 01/10/2019
Internet address	https://www.esmo.org/Conferences/Past-Conferences/ESMO-Congress-2019

@article{d822f78eed5a432f9f99ae5ea6c000c5,

title = "Can tocotrienol reduce time to the first serious adverse event during treatment with FOLFOXIRI for colorectal cancer?",

author = "{Raunkilde Larsen}, Louise and Hansen, {Torben Fr{\o}strup} and Anders Jakobsen and Jensen, {Lars Henrik}",

year = "2019",

doi = "10.1093/annonc/mdz394.026",

language = "English",

volume = "30",

pages = "v871",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Heinemann",

number = "Suppl. 5",

note = "null ; Conference date: 27-09-2019 Through 01-10-2019",

url = "https://www.esmo.org/Conferences/Past-Conferences/ESMO-Congress-2019",

}

In: Annals of Oncology, Vol. 30, No. Suppl. 5, 2019, p. v871.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review